Orthofix Medical Inc. · NASDAQ:OFIX
Orthofix Medical — Investor Presentation (March 2024)
22 slides from Orthofix Medical's investor presentation, Mar 5, 2024
Slide 1: Corporate Investor Deck March 2024
Corporate Investor Deck March 2024
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, relating to our business and financial outlook, which are based on our cur
Slide 3: Investment Highlights
a Investment Highlights Building a Leading Global Spine & Orthopedics Company Extensive Portfolio Solutions with Complementary Technologies Improved Clinical Outcomes & Economic Value Expanded Distribution Channels & Global Commercial Reach $150M Credit Facility Provides Liquidity to Fund Growth and
Slide 4: Senior Leadership Team
Senior Leadership Team Experienced leadership with 250+ years in spine/orthopedics Julie Andrews Chief Financial Officer Roberto Donadello Senior Vice President Global Operations Jason Shallenberger President Global Enabling Technologies Beau Standish, PhD, Peng President Global Enabling Technologie
Slide 5: Complementary High Growth Portfolio
Complementary High Growth Portfolio SmartTRAK® 2022 – 2026 U.S. Estimates *Focused growth segments include Enabling Technologies, Motion Preservation, Interbody, DBM, LLIF/OLIF, MIS and Long Bone Stimulation $7B of Focused High-Growth Market Segments* | 6.1% CAGR Motion Preservation Spinal Fixation
Slide 6: Orthopedics
Orthopedics Specialized portfolio of limb reconstruction and deformity correction products that address the most challenging orthopedic conditions Complex Fracture Management Digital Healthcare Adult & Pediatric Limb Reconstruction Complex Foot & Ankle Reconstruction TrueLok™ Ring Fixation System Tr
Slide 7: Spinal Implants
Cervical Thoracolumbar Fixation Interbodies Spinal Implants Comprehensive best-in-class spinal portfolio driving rapid market adoption M6-C™ Artificial Cervical Disc Explorer® TO Expandable Interbody Construx™ Mini PTC Spacer System with Nanovate™ Technology Reef® TO NanoMetalene® with Reef Topograp
Slide 8: Biologics
Demineralized Bone Putty Demineralized Bone Fiber Cellular Allograft Biologics Full spectrum of biologic solutions to enhance the fusion process and promote bone repair and growth Procedural Solutions Traditional Allograft Graft Delivery Synthetic Trinity Elite™ OsteoStrand® Plus Torrent® & Torrent
Slide 9: Bone Growth Therapies
Bone Growth Therapies Bone Healing Therapy Spine Fusion Therapy Safe and effective treatment and non-surgical alternative to overcome bone healing challenges AccelStim™ Bone Healing Therapy PhysioStim™ Bone Growth Therapy CervicalStim™ Spinal Fusion Therapy SpinalStim™ Spinal Fusion Therapy # 1 Pres
Slide 10: Enabling Technologies
Enabling Technologies Servicing the full continuum of surgical care FLASH™ Navigation with 7D Technology Machine-vision Navigation System
Slide 11: Diversified & Complementary Business with Broad Commercial Reach
Diversified & Complementary Business with Broad Commercial Reach ~83% U.S. | ~17% OUS Products distributed in 60+ countries $747M* TTM Revenue *As of December 31, 2023
Slide 12: Commercial Strategy Framework
Commercial Strategy Framework Geographic Footprint Double digit growth in global commercial reach Focused Distributors Expanded market penetration with increased dedicated distribution Diverse Sales Strategy Cross selling opportunities across direct and distribution-based sales channels Clinical Rel
Slide 13: Key Growth Drivers
Key Growth Drivers Orthopedics HSD growth driven by channel expansion and further products launches expanding our leading TrueLok™ and Fitbone™ franchises Spinal Fixation Industry leading product and procedure launches per year & continued penetration into emerging markets Product Utilization Higher
Slide 14: Q4 and FY 2023 Highlights
Q4 and FY 2023 Highlights Constant Currency is calculated by applying foreign currency rates applicable to the comparable, prior-year period to present the current period net sales at comparable rates. Constant currency can be presented for numerous GAAP measures, but is commonly used by management
Slide 15: 2024 Full Year Guidance
2024 Full Year Guidance* $785 – 795M Revenue $62 – 67M Adjusted EBITDA Revenue ranges above represent 5% to 7% year-over-year growth Guidance information is as of March 5, 2024, based on guidance provided by Orthofix leadership on that date. Inclusion of this information in this presentation is not
Slide 16: Merger Highlights
Broader Commercial Reach Accelerated adoption of differentiated technologies Sustainable growth & value creation Strengthened U.S. and international sales channels Rapid product innovation driving market-share taking Complementary Portfolios #1 Prescribed bone growth stimulator portfolio in the U.S.
Slide 17: Investment Highlights
a Investment Highlights Building a Leading Global Spine & Orthopedics Company Extensive Portfolio Solutions with Complementary Technologies Improved Clinical Outcomes & Economic Value Expanded Distribution Channels & Global Commercial Reach $150M Credit Facility Provides Liquidity to Fund Growth and
Slide 18: Thank You
Click to edit Master title style THANK YOU
Slide 19: Appendix A
APPENDIX A QORTHOFIx: “% SeaSpine
Slide 20: Proforma Non-GAAP Financial Measures
Proforma Non-GAAP Financial Measures On the Company’s Q4 2023 earnings call held on March 5, 2024, Orthofix management presented Proforma Adjusted EBITDA and Adjusted Proforma Gross Margin, both of which are non-GAAP financial measures, for the 4th quarter of 2022. Those proforma non-GAAP financial
Slide 21: Historical 2022 Quarterly Proforma Adjusted EBITDA
Historical 2022 Quarterly Proforma Adjusted EBITDA On the Company’s Q4 2023 earnings call held on March 5, 2024, Orthofix management presented Proforma Adjusted EBITDA and Adjusted Proforma Gross Margin, both of which are non-GAAP financial measures, for the 4th quarter of 2022. Those proforma non-G
Slide 22: Historical 2022 Quarterly Proforma Adjusted Gross Margin
Historical 2022 Quarterly Proforma Adjusted Gross Margin On the Company’s Q4 2023 earnings call held on March 5, 2024, Orthofix management presented Proforma Adjusted EBITDA and Adjusted Proforma Gross Margin, both of which are non-GAAP financial measures, for the 4th quarter of 2022. Those proforma
Orthofix Medical — Investor Presentation (March 2024) on 6ix